NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New strategy zaps lung cancer spots before they grow
Disease control CompletedThis study tested whether giving focused treatments (like heat or freezing) to cancer spots in the body can help control advanced lung cancer that has spread. The approach uses a blood test to find tiny bits of cancer DNA (minimal residual disease) and treats when levels rise. 37…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New combo offers hope for lung cancer patients resistant to targeted drugs
Disease control CompletedThis study tested a combination of chemotherapy (platinum and pemetrexed) plus an immunotherapy drug (atezolizumab), with or without another drug (bevacizumab), in 150 adults with advanced non-squamous lung cancer that has specific gene changes (EGFR, ALK, or ROS1) and has stoppe…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated May 15, 2026 11:52 UTC
-
New combo shows promise for tough lung cancer
Disease control CompletedThis study tested a new drug combination (bemcentinib plus pembrolizumab) in 99 people with advanced lung adenocarcinoma that had already been treated. The goal was to see if the combo could shrink tumors or slow the cancer. Participants were grouped based on their prior treatmen…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: BerGenBio ASA • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New PET scan may predict immunotherapy success in lung cancer
Knowledge-focused CompletedThis study tested a new type of PET scan that looks for a protein called PD-L1 on cancer cells. The goal was to see if this scan could predict which patients with advanced lung cancer would benefit from the immunotherapy drug nivolumab. Eighty patients received the scan before st…
Matched conditions: NSCLC STAGE IV
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC